Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2022

View Archived Issues

New phospholipid anticancer target identified

Single-use digestive cartridge improves fat and nutrient absorption in a porcine SBS model

ROR2 CAR T cells exhibit cytotoxic effects against tumoral cells

CD70-CAR NK cells have cytotoxic effects against osteosarcoma

Auransa identifies new agents for bacterial and fungal infections

New CTP synthase 1 inhibitors discovered at Nimbus Clotho

Mount Sinai School of Medicine patents ATP6V1A gene expression enhancers

Spectrum Pharmaceuticals divulges G12C mutant GTPase KRAS inhibitors

Chulalongkorn University presents compounds for treating hepatitis B virus infections

Novel mouse models of RP59 retinal degeneration

HDAC6 inhibitor CKD-510 shows promise for the treatment of CMT1A

Preclinical studies of JAG-101, a gene therapy for type 1 galactosemia

Clearmind's MEAI shows suppressive effect on alcohol consumption in mice

ORT-247 demonstrates efficacy in preclinical models of CMT and ALS

Myrtelle enters licensing agreement with Rescue Hearing for gene therapy for genetic hearing loss

FDA grants orphan drug designation to XMT-2056 for gastric cancer

PostEra's AI approach to accelerate NIH-funded work for pandemic preparedness

Biomea nominates third-generation FLT3 inhibitor as IND candidate

Blue Water Vaccines collaborates with Instituto Butantan on universal influenza vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...